Syngene International Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹828
- Today's High:
- ₹858.35
- Open Price:
- ₹840
- 52W Low:
- ₹535.1501
- 52W High:
- ₹843
- Prev. Close:
- ₹839.2
- Volume:
- 43450
Company Statistics
- Market Cap.:
- ₹310.96 billion
- Book Value:
- 90.298
- Revenue TTM:
- ₹33.56 billion
- Operating Margin TTM:
- 19.44%
- Gross Profit TTM:
- ₹23.33 billion
- Profit Margin:
- 14.42%
- Return on Assets TTM:
- 6.77%
- Return on Equity TTM:
- 13.43%
Company Profile
Syngene International Limited had its IPO on under the ticker symbol SYNGENE.
The company operates in the Healthcare sector and Biotechnology industry. Syngene International Limited has a staff strength of 6,847 employees.
Stock update
Shares of Syngene International Limited opened at ₹840 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹828 - ₹858.35, and closed at ₹833.05.
This is a -0.73% slip from the previous day's closing price.
A total volume of 43,450 shares were traded at the close of the day’s session.
In the last one week, shares of Syngene International Limited have increased by +4.87%.
Syngene International Limited's Key Ratios
Syngene International Limited has a market cap of ₹310.96 billion, indicating a price to book ratio of 7.1761 and a price to sales ratio of 8.6378.
In the last 12-months Syngene International Limited’s revenue was ₹33.56 billion with a gross profit of ₹23.33 billion and an EBITDA of ₹10.07 billion. The EBITDA ratio measures Syngene International Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Syngene International Limited’s operating margin was 19.44% while its return on assets stood at 6.77% with a return of equity of 13.43%.
In Q2, Syngene International Limited’s quarterly earnings growth was a positive 26.8% while revenue growth was a positive 25.4%.
Syngene International Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 64.2976
- PEG
Its diluted EPS in the last 12-months stands at ₹12.03 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Syngene International Limited’s profitability.
Syngene International Limited stock is trading at a EV to sales ratio of 8.6006 and a EV to EBITDA ratio of 25.8982. Its price to sales ratio in the trailing 12-months stood at 8.6378.
Syngene International Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0.07% and a payout ratio of 4.17%.
Balance sheet and cash flow metrics
- Total Assets
- ₹58.31 billion
- Total Liabilities
- ₹11.88 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 4.17%
Syngene International Limited ended 2024 with ₹58.31 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹58.31 billion while shareholder equity stood at ₹36.18 billion.
Syngene International Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹11.88 billion in other current liabilities, 4014000000.00 in common stock, ₹32.17 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹895.00 million and cash and short-term investments were ₹14.11 billion. The company’s total short-term debt was ₹0 while long-term debt stood at ₹4.89 billion.
Syngene International Limited’s total current assets stands at ₹24.25 billion while long-term investments were ₹0 and short-term investments were ₹13.22 billion. Its net receivables were ₹5.29 billion compared to accounts payable of ₹2.58 billion and inventory worth ₹3.33 billion.
In 2024, Syngene International Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Syngene International Limited paid ₹0.04 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹833.05
- 52-Week High
- ₹843
- 52-Week Low
- ₹535.1501
- Analyst Target Price
- ₹
Syngene International Limited stock is currently trading at ₹833.05 per share. It touched a 52-week high of ₹843 and a 52-week low of ₹843. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹793.23 and 200-day moving average was ₹668.66 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5543.7% of the company’s stock are held by insiders while 2530.2% are held by institutions.
Frequently Asked Questions About Syngene International Limited
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, Japan, Europe, the United States, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; and discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing services. In addition, the company provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical, central lab, clinical data management, regulatory, biostatistics, and medical writing services. Further, it offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. The company serves pharmaceutical, biotechnology, nutrition, animal health, consumer goods, specialty chemical, and other companies. It has partnerships and collaborations with Bristol-Myers Squibb Co.; Baxter Inc.; and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.